Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Inhibikase Therapeutics
Biotech
Private equity firms take over bluebird's nest—Chutes & Ladders
Private equity firms take over bluebird’s nest. Novartis vet vaults to FoRx. Indivior IDs next CEO.
Darren Incorvaia
,
Zoey Becker
Feb 28, 2025 8:30am
NIH leaders join health agency exodus—Chutes & Ladders
Feb 21, 2025 8:30am
Inhibikase hits pause on Parkinson's program over efficacy
Jan 30, 2025 4:30am
Inhibikase clears another clinical hold, preps new phase 2 trial
Mar 8, 2023 10:18am
Inhibikase, FDA agree on terms to lift Parkinson's drug hold
Jan 25, 2023 11:24am
Inhibikase stock sinks on FDA clinical hold of Parkinson's drug
Nov 7, 2022 9:25am
